Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Investor Presentation (October 2023)
31 slides from Neuroscientific Biopharmaceuticals's investor presentation, Oct 31, 2023
Slide 1: ASX Announcement: Investor Update Webinar
ASX ANNOUNCEMENT 31 OCTOBER 2023 INVESTOR UPDATE WEBINAR NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) (“NeuroScientific” or “the Company”) wishes to advise shareholders and investors that the Company will be conducting a live investor update on Tuesday 31st October 2023. A copy of the investor p
Slide 2: About NeuroScientific Biopharmaceuticals Ltd
About NeuroScientific Biopharmaceuticals Ltd NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide- based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinB™, a ther
Slide 3: Novel Drug Therapies for Neurodegenerative Conditions
For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS CEO Review of EmtinB Project TM 31 October 2023 neuroscientific.com
Slide 4: Disclaimer
DISCLAIMER The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd For personal use only (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex
Slide 5: Background
BACKGROUND • NeuroScientific Biopharmaceuticals Ltd (NSB) has been developing a peptide-based product EmtinBTM for the For personal use only treatment of neurodegenerative conditions such as Alzheimer’s disease, Multiple Sclerosis and Glaucoma. • EmtinBTM (Figure 2) is a peptide modeled on the β-dom
Slide 6: EmtinB is a novel lead drug candidate
EMTINBTM IS A NOVEL LEAD DRUG CANDIDATE For personal use only neuroscientific.com • 4
Slide 7: Project Review
PROJECT REVIEW • Over the past six weeks since mid-September 2023 the Company’s CEO Stephen Carter has worked with the For personal use only Board, executive team and key consultants, in conducting a full analysis and review of the NeuroScientific’s Research and Development programs of EmtinB™ for u
Slide 8: Project Review: Highlights
PROJECT REVIEW: Highlights ▪ EmtinBTM targets LRP-1. For personal use only ▪ MoA has potential for multiple treatment indications. ▪ EmtinBTM preclinical data has demonstrated: ▪ Neuroprotection in cell survival models >90%; ▪ Significant axonal regeneration (including significant results in spinal
Slide 9: EmtinB: Novel Therapeutic Target
EMTINBTM : NOVEL THERAPEUTIC TARGET LRP-1 activates protective signalling pathways For personal use only EmtinB™ binds here EmtinBTM binds to LRP-1 receptors of neurons, stimulating survival and regeneration. neuroscientific.com • 7
Slide 10: EmtinB Mechanism of Action: Binding LRP-1 receptor
EMTINB MECHANISM OF ACTION: Binding LRP-1 receptor For personal use only neuroscientific.com • 8
Slide 11: Target Receptor Studies
TARGET RECEPTOR STUDIES For personal use only EmtinBTM binds LRP1 as demonstrated using surface plasmon resonance studies (Figure 3). Pre-bound LRP antagonist, receptor associated protein-1 (RAP), inhibited the binding of EmtinBTM to LRP1 (Figure 4). neuroscientific.com • 9
Slide 12: Target Receptor Studies (continued)
TARGET RECEPTOR STUDIES (continued) • ERK, PKB/Akt and CREB are downstream For personal use only signaling molecules that can be linked to either direct or indirect activation pathways as a result of LRP1 ligand binding. • Both ERK and PKB/Akt are positively associated with pathways of neuronal surv
Slide 13: Project Review: General Studies
PROJECT REVIEW: General Studies • The early work evaluated the effect of EmtinB™on nerve regeneration For personal use only and we saw a statistically significant increase in the mean neurite length, synaptic density, neural survival, oligodendrocyte proliferation and myelin formation. • Thus, confi
Slide 14: Project Review: Safety
PROJECT REVIEW: Safety • Studies evaluating the Central Nervous System Safety Pharmacology, Cardiovascular Safety Pharmacology and For personal use only Respiratory Safety Pharmacology of EmtinB™ confirmed the overall lack of any key safety concerns of EmtinB™. • EmtinB™ was shown not to be mutageni
Slide 15: Project Review: Systemic projects
PROJECT REVIEW: Systemic projects • EmtinB™ has shown considerable therapeutic potential in the laboratory and pre-clinical animal models For personal use only of AD and MS. • In our preclinical mouse model of MS we saw statistically significant functional improvement in the EmtinB™ treated animals.
Slide 16: EmtinB action in Neurodegenerative diseases of the eye
EmtinB™ action in Neurodegenerative diseases of the eye. For personal use only neuroscientific.com • 14
Slide 17: Metallothionein II: Optic Nerve Study
METALLOTHIONEIN II: OPTIC NERVE STUDY MTII INDUCED REGENERATION OF THE For personal use only OPTIC NERVE IN RATS • In a study the optic nerve of a rat was severed. • One group was treated with Metallothionein II and the other untreated. • The treated group regrew the optic nerve. neuroscientific.com
Slide 18: EmtinB promotes survival of retinal ganglion cells and protects the optic nerve
EMTINBTM promotes survival of retinal ganglion cells and protects the optic nerve • We evaluated where EmtinB™ was distributed in the For personal use only eye. The study confirmed that EmtinB™ was distributed through-out the eye and was seen in the optic nerve and nerve head. There were no signs of
Slide 19: Project Review: Ophthalmology Projects
PROJECT REVIEW: Ophthalmology Projects • In the ophthalmology studies EmtinB™ is For personal use only presented as an injection (IVT) into the vitreous humour of the eye. Whilst this sounds unfavourable, it is a normal way of treating ocular disease. • We have evaluated the distribution of EmtinB™
Slide 20: Project Review: Ophthalmology Projects
PROJECT REVIEW: Ophthalmology Projects For personal use only • A 13-week study in NHP’s looked at multiple (4) injections into the eye with a 4-week washout. From this study we noted the presence of EmtinB™ in the eye at all concentrations and determined a safe injection concentration (NOAEC) of 150
Slide 21: Project Review: Ophthalmology Projects
PROJECT REVIEW: Ophthalmology Projects • The proposed route of Administration and therapeutic focus opens opportunities to increase Intellectual For personal use only Property. • There are other neurological ocular diseases (e.g. ischaemic optic neuropathy (ION)) that provide an opportunity to apply
Slide 22: Glaucoma Opportunity
GLAUCOMA OPPORTUNITY • Glaucoma is the leading cause of irreversible blindness in Australia and is rapidly increasing in prevalence due to an For personal use only aging population. Other risk factors associated with glaucoma, such as high myopia, are also projected to increase exponentially in the
Slide 23: Early Treatment Is the Key
EARLY TREATMENT IS THE KEY Pathology Neuronal Loss Irreversible For personal use only Late Vascular defects damage Blindness Reversible Pathology Oxidative stress damage Early Neuronal dysfunction Neuroregeneration: Vascular dysfunction Aim is to repair or activate residual vision Treat with EmtinBT
Slide 24: Project Review: Ophthalmology Projects Summary
PROJECT REVIEW: Ophthalmology Projects Summary • The proposed treatment of Glaucoma or one of the other potential neurodegenerative diseases of the eye is For personal use only not done at home; it is carried out in a medical facility. This changes the product dynamics. • The current drug formulatio
Slide 25: Development of EmtinB for Ophthalmological Use
DEVELOPMENT OF EMTINBTM FOR OPTHALMOLOGICAL USE For personal use only Active sequences from MT- 2-week study in rabbits 3 2-week study in Rabbits 3 Phase 1 study being II protein identified doses No safety concerns. doses designed 2 peptides on the β-domain Confirmed the drug No safety concerns Pre-
Slide 26: Commercialisation Strategy
COMMERCIALISATION STRATEGY For personal use only The Company’s commercialisation strategy involves developing its drug candidates through to successful completion of Phase II clinical studies and then license them to a pharmaceutical or biotechnology company for further clinical development / market
Slide 27: R&D Strategy and Indicative Schedule
R&D STRATEGY AND INDICATIVE SCHEDULE Ophthalmology Project 2023 2024 2024 2024 2024 2025 2025 2025 2025 For personal use only Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FDA Pre-IND Type B meeting 13-week GLP tox study (rabbits) Phase 1 HREC Phase 1a study Phase 1b studies Review of RoA Phase 2 enabling studies Phas
Slide 28: Board and Leadership
For personal use only BOARD AND LEADERSHIP Dr Anton Uvarov, PhD, Stephen Quantrill, Paul Rennie MBM, Dr Linda Friedland Abby Macnish Stephen Carter MBA MBA MSTC NON-EXECUTIVE Niven,CFA CHIEF EXECUTIVE NON-EXECUTIVE NON-EXECUTIVE NON-EXECUTIVE DIRECTOR COMPANY OFFICER DIRECTOR DIRECTOR CHAIR SECRETAR
Slide 29: Financial Metrics and Milestones
FINANCIAL METRICS AND MILESTONES FINANCIALS CAPITAL STRUCTURE For personal use only ▪ ~$4M cash on hand ASX code NSB ▪ Sufficient cash to develop lead project to clinical trials. Shares on issue 143M Price $0.06 TARGET MILESTONES* Market cap $8.6M ▪ Q1 2024 – Lodge Pre-IND meeting request with FDA M
Slide 30: Summary
SUMMARY • The Company has conducted an EmtinB™ project review & confirms EmtinB™ as highly prospective as NSB’s lead For personal use only project. • EmtinBTM for the treatment of neurodegenerative diseases of the eye has shown great promise. • >5% of the global population suffer vision loss due to
Slide 31: For more information please contact
For personal use only neuroscientific.com For more information please contact: Stephen Carter Chief Executive Officer [email protected]
NeuroScientific Biopharmaceuticals — Investor Presentation (October 2023) on 6ix